Transplantation for hilar cholangiocarcinoma.
1. Patients with primary sclerosing cholangitis (PSC) have a 8 to 12% risk of developing cholangiocarcinoma (CCA). 2. Cytologic techniques for aneuploidy such as digital image analysis and fluorescence in situ hybridization increase the detection rate for CCA. 3. Survival following resection for CCA is 20% to 40% at 5 years. 4. Survival following liver transplantation for unresectable, perihilar CCAs, mass lesion if present <3 cm, is greater than 80% at 5 years. 5. Patients with intrahepatic CCAs are not eligible for liver transplantation.
Heimbach
Julie K
JK
William J von Liebig Transplant Center, Mayo Clinic College of Medicine, Rochester, MN, USA.
Haddock
Michael G
MG
Alberts
Steven R
SR
Nyberg
Scott L
SL
Ishitani
Michael B
MB
Rosen
Charles B
CB
Gores
Gregory J
GJ
D001650:Bile Duct Neoplasms / Q000175:diagnosis / Q000601:surgery*; D001653:Bile Ducts, Intrahepatic; D018281:Cholangiocarcinoma / Q000175:diagnosis / Q000601:surgery*; D002985:Clinical Protocols; D015276:Health Care Rationing; D006801:Humans; D016031:Liver Transplantation; D016019:Survival Analysis; D016896:Treatment Outcome